用吸入疗法评估喘临床缓解:CAPTAIN的后期分析
John Oppenheimer1, Ian D Pavord2,3, Tom Corbridge4
1University of Medicine and Dentistry of New Jersey-Rutgers, Newark, NJ, USA.
Advances in therapy
|December 24, 2025
概括
在中度至重度喘患者使用吸入式酸/乌克利迪尼/维兰特醇 (FF/UMEC/VI) 时,可以实现临床缓解 (CR). 这种三重疗法与FF/VI相比显示出更高的CR率,支持CR作为可实现的喘治疗目标.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 临床缓解 (CR) 是喘治疗的新兴治疗目标.
- 通过吸入治疗实现CR的证据是有限的.
- 这项研究评估了中度至重度喘中CR的可达性.
研究的目的:
- 评估实现复合临床缓解终点的可行性.
- 为了比较吸入式黄酸盐/尤克利迪尼/维兰特醇 (FF/UMEC/VI) 与黄酸盐/维兰特醇 (FF/VI) 的疗效.
- 为了确定CR是否是一种可实现的喘治疗目标.
主要方法:
- 对CAPTAIN IIIA期试验的特异分析 (NCT02924688).
- 没有控制的中度至重度喘患者每天接受FF/UMEC/VI或FF/VI一次.
- CR定义为无系统性皮质类固醇,无严重恶化,ACQ-5 <1.50,以及24周和52周的肺功能改善/稳定性的复合物.
主要成果:
- 与FF/UMEC/VI相比,在第24周和第52周观察到更高的CR率,用于肺功能稳定和优化.
- 在第24周,FF/UMEC/VI表现出更高的几率和实现CR的概率.
- 更严格的喘控制问卷 (ACQ-5) 门导致较少的患者符合CR标准.
结论:
- 在中度至重度喘中,通过吸入疗法可以实现临床缓解.
- 与FF/VI相比,FF/UMEC/VI在实现CR方面表现出更高的有效性.
- 对喘患者来说,CR应该被视为一个可行的治疗目标.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
01:30Asthma-IV: Nursing Management
3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.7K
01:24Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
01:26COPD: Management Using Bronchodilators and Corticosteroids
692
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
692
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K